Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
Isoxazole 9 (also known as Isx-9) is a synthetic promotor/inducer of adult neurogenesis by triggering neuronal differentiation of adult neural stem/precursor cells (NSPCs). Isx-9 promotes neurogenesis in vivo, enhancing the proliferation and differentiation of hippocampal subgranular zone (SGZ) neuroblasts, and the dendritic arborization of adult-generated dentate gyrus neurons. Isx-9 also improves hippocampal function, enhancing memory in the Morris water maze. Notably, Isx-9 enhances neurogenesis and memory without detectable increases in cellular or animal activity or vascularization.
ln Vitro |
ISX-9 stimulates dendritic differentiation of adult-derived dentate gyrus neurons and increases the proliferation and differentiation of hippocampus subgranular zone (SGZ) neuroblasts. It also promotes neurogenesis in vivo. It has been demonstrated that ISX-9, at 2.5–20 μM, inhibits glioblastoma via activating calcium-activated signaling pathways that rely on myocyte enhancer factor 2-dependent gene expression and dose-dependently stimulates neurogenesis in adult rat hippocampus stem cells. cell production [1]. Myocyte enhancer protein family (Mef2) was implicated in the regulation of ISX-9-induced neurogenesis, according to molecular exploration conducted using FACS and microarrays of SGZ stem and progenitor cells [1].
|
---|---|
ln Vivo |
Infarcted mice's cardiac remodeling was reversed by EV generated from CPCISX-9[1].
|
Animal Protocol |
Animal/Disease Models: NOD/SCID (severe combined immunodeficient) mouse[1]
Doses: 20 μL (CPCISX-9) Route of Administration: CPCISX-9 were injected into the myocardium along the border zone. Experimental Results: (EV-CPCISX-9) Promoted CM proliferation and angiogenesis and reversed ventricular remodeling in mice post MI. |
References |
[1]. Petrik D, et al. Functional and mechanistic exploration of an adult neurogenesis-promoting small molecule. FASEB J. 2012 Aug;26(8):3148-3162.
[2]. Jay W Schneider, et al. Small-molecule activation of neuronal cell fate. Nat Chem Biol. 2008 Jul;4(7):408-10. [3]. Jamie L Russell, et al. Targeting native adult heart progenitors with cardiogenic small molecules. ACS Chem Biol. 2012 Jun 15;7(6):1067-76. |
Molecular Formula |
C11H10N2O2S
|
|
---|---|---|
Molecular Weight |
234.27
|
|
CAS # |
832115-62-5
|
|
Related CAS # |
|
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
|
SMILES |
O=C(C1=NOC(C2=CC=CS2)=C1)NC3CC3
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.67 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (10.67 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (10.67 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 5% DMSO +55%PEG 300 +ddH2O: 10mg/mL |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 4.2686 mL | 21.3429 mL | 42.6858 mL | |
5 mM | 0.8537 mL | 4.2686 mL | 8.5372 mL | |
10 mM | 0.4269 mL | 2.1343 mL | 4.2686 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.